Oruka Therapeutics
ORKA
22 hedge funds and large institutions have $2.6M invested in Oruka Therapeutics in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
58% more call options, than puts
Call options by funds: $223K | Put options by funds: $141K
10% more funds holding
Funds holding: 20 → 22 (+2)
8% more capital invested
Capital invested by funds: $2.41M → $2.6M (+$196K)
0.01% more ownership
Funds ownership: 0.65% → 0.66% (+0.01%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$110K |
| 2 |
VF
Virtu Financial
New York
|
+$49.3K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$45.3K |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$35.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$28.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$123K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$66.2K |
| 3 |
Millennium Management
New York
|
-$35.2K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$26K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.28K |
ORKA Hedge Fund Activity: Q1 2022 in Review
22 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2022, worth a combined $2.6M — up 8.1% from $2.41M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ORKA positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $110K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $123K sold.
- 22 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2022, up from 20 in Q4 2021.
- Funds reported $2.6M of Oruka Therapeutics stock for Q1 2022, up 8.1% quarter-over-quarter.
- 5 funds opened new Oruka Therapeutics positions in Q1 2022 and 3 closed out, a net change of +2 holders.
- The largest Oruka Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $110K added.
- The largest Oruka Therapeutics seller in Q1 2022 was Acadian Asset Management, an estimated $123K sold.
Based on aggregated 13F filings for Q1 2022.